Humphries, Matthew P.Craig, Stephanie G.Kacprzyk, RafalFisher, Natalie C.Bingham, VictoriaMcQuaid, StephenMurray, Graeme I.McManus, DamianTurkington, Richard C.James, JacquelineSalto-Tellez, Manuel2020-06-032020-06-032020-06-01Humphries, M P, Craig, S G, Kacprzyk, R, Fisher, N C, Bingham, V, McQuaid, S, Murray, G I, McManus, D, Turkington, R C, James, J & Salto-Tellez, M 2020, 'The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation', BMC Cancer, vol. 20, 500. https://doi.org/10.1186/s12885-020-06987-y1471-2407ORCID: /0000-0003-3981-2420/work/76973683https://hdl.handle.net/2164/14430Acknowledgments The samples used in this research were received from the Northern Ireland Biobank, which has ethical approval to use de-identified tissue samples from the Belfast Health and Social Care Tissue Pathology archive (REC:11/NI/0013). The Northern Ireland Molecular Pathology Laboratory, was responsible for construction of tissue microarrays, slide staining, and scanning. We are grateful to the NVIDIA Corporation for supporting our research via the GPU Grant Program for researchers. The research leading to these results has also received funding from Invest Northern Ireland. The authors thank Mr. Ken Arthur for the construction of the original tissue microarrays used in this study. Funding This study was funded by a CRUK Accelerator Grant (A20256) to JJ and MST. CRUK had no role in the study design, collection, analysis, and interpretation of the data or in the writing of the report.112137791engSDG 3 - Good Health and Well-beingEsophageal adenocarcinomaImmune checkpointMultiplex IHCImage analysisBIOMARKERSSURVIVALPROGRAMMED DEATH-1PROGNOSTIC-SIGNIFICANCELARGE COHORTCANCERLIGAND 1 EXPRESSIONR Medicine (General)GeneticsOncologyCancer ResearchCancer Research UKA20256Supplementary DataR1Journal article10.1186/s12885-020-06987-yhttp://www.scopus.com/inward/record.url?scp=85085910113&partnerID=8YFLogxK20